CLINICAL_TRIALS trial_result · 2022-03-31

Clinical Trial Update: A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy [Phase 2]

Phase 2 rollover study assessing ARRY-371797 in LMNA-related dilated cardiomyopathy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Pfizer | Conditions: LMNA-Related Dilated Cardiomyopathy | Phase 2 | Status: COMPLETED | Results posted: 2022-03-31